Manchester University NHS Foundation Trust
mft.nhs.ukLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
138
Active
19
Phase 3
2
Total enrollment
76,595
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care | — | — | — | — | — | 1 | |
| Antifungals as standard of care | — | — | — | — | — | 1 |
Next readouts
- 2026-11
Top conditions
- Diabetes Mellitus, Type 16
- Breast Cancer5
- Heart Failure4
- Asthma4
- Cardiovascular Diseases3
- Chronic Cough3
- Sepsis3
- Hernia2
Frequently asked questions about Manchester University NHS Foundation Trust
- How many clinical trials does Manchester University NHS Foundation Trust have on ClinicalTrials.gov?
- Manchester University NHS Foundation Trust is listed as the lead sponsor on 138 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Manchester University NHS Foundation Trust's trials are in Phase 3?
- 2 of Manchester University NHS Foundation Trust's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Manchester University NHS Foundation Trust focus on?
- Manchester University NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Diabetes Mellitus, Type 1, Breast Cancer, Heart Failure, Asthma, Cardiovascular Diseases.
- When are Manchester University NHS Foundation Trust's next clinical trial readouts?
- Manchester University NHS Foundation Trust has 1 upcoming primary-completion readout tracked here; the soonest is “Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study”, expected around 2026-11.